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Contrast Media Cost Analysis-1
The clinical economic assessment of low versus high osmolality
contrast media in angiocardiography by Powe et al
. (1) calculated
the net costs from three different cost perspectives
. They concluded
that the cost of side effects associated with high osmolality contrast
media partially offset the higher cost of low osmolality contrast
media, depending on the cost perspective
. Their study represented
one of the most comprehensive assessments to date, featuring the
cost of four degrees of adverse effects
.
Two significant concerns exist with their methods
. First, the
assignment of adverse event costs may have been skewed by
insufficient methodology . The authors used means to represent
central tendencies per treatment group
. However, in their Table 4 .
they demonstrated that there were no significant differences be-
tween the treatment groups in mean costs per adverse event
category. Use of the mean per group, however, assigned a much
higher expected cost to the high osmolality group
. A more balanced
approach would have used the pooled mean cost per adverse event
category assigned to both treatment groups
. The weighted expected
cost of adverse events per group would still have been fairly driven
by the significant difference in incidence between treatment groups
.
The authors partially attempted this approach by using sensitivity
analysis to analyze only the pooled cost of severe adverse evt
:as .
The mild and moderate adverse event categories were much greater
in incidence, and the difference between groups was statistically
significant .
Second, as pointed out in their Discussion, the costs and efrecty
of prophylactic treatment were not assessed
. !n the Results . allergic
reactions and those associat : with cardiac conduction effects
(2) were not separated
. Estitr - ing that 60% of all reactions to high
osmolality contrast media w, . allergy-mediated, explaining at least
40% of adverse effect costs, use of hydroxyzine (25 mg) and
cimetidine (300 mg) prophylaxis (3) ($1 .80 average wholesale price)
with assumed 80 risk reduction could have decreased the hospital
average and hospital differential costs associated wit!. side etfectc of
high osmolality contrast media by one-third . This would have
increased the negative differences in hospital average costs to $132
and hospital differential cost to $165 .
These two areas provide opportunity fur more evaluative report-
ing of data and the need to study the economic benefit of prophylaxis
with effective, inexpensive antihistamines . The comparison of high
and low osmolality contrast media without adverse event prophy-
laxis may be neither clinically nor economically relevant in the near
future .
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Powe et al . (1) have attempted to provide the kind of well considered
cost analysis needed to bring the debate over use of nonionic
contrast media into proper perspective
. It has long been debated
whether the cost of treating mild and moderate adverse events and
the attendant delay in completing procedures totally or only partially
offsets the cost advantages as
:,aciated with the use of an ionic agent .
In the present study as in a previously published evaluation (2),
Powe et al . argue that the cost of treating adverse reactions after
ionic high osmolality contrast media only partially offsets the
increased cost associated with the use of low osmolality contrast
media. They calculate that the savings realized through lower costs
for treating adverse events with low osmolality contrast media
offsets -751% of the average cost to society of use of low osmolality
agents and 33% of the hospital's differential cost (low vs
. high
osmolality contrast media) and conclude that the latter agents are
more cost-effective for angiographic procedures in low risk patients
.
However, a critical reading of their results may prove the opposite
to be true .
There are several problems with the assumptions made by Powe
et a! . in calculating the cost-effectiveness of low versus high
osmolality contrast media . I) The entire exercise is predicated on a
comparison of two strategies: universal use of high osmolality
contrast media or universal use of low osmolality contrast media . As
universal high osmolality contrast media use is inconsistent with
well accepted standards of practice in the medical community, this
all or nothing approach overemphasizes the potential cost savings
attributable to use of these agents in specific patient groups and
ignores significant medicolegal issues . 2) The reported costs per
procedure are inconsistent with current pricing and dosing regimens
for contrast media . Powe et al . report using 212 ml of contrast
material per study, whereas the average volume used for these
procedures in most hospitals is closer to 130 ml (3)
. The per-
procedure contrast media costs given by the authors are $8 for + nic
and $215 for nonionic contrast media, with a cost differential of $207
.
However, today 200 ml of an ionic agent sells for - , whereas the list
price for a I50-ml vial of the nonionic Isovue-370 is -$138
.
With current pricing, the average procedure using the nonionic
agent would need to involve >230 ml to approach the per-procedure
cost cited by the authors . Clearly, this ilgure is inconsistent with
current dosage patterns . A similar analysis with today's prices and
an average per-procedure volume of 150 ml would result in a cost
differential between low and high osmolality contrast media of $130
($138 minus $8)
. If the incidence of adverse reactions and treatment
costs ($92 for low, $249 for high osmolality contrast media) were
kept constant, and current contrast media list prices were substi-
tuted, use of low rather than high osmolality contrast media could
provide a cost savings of $27/study from a societal perspective ($230
for low vs. $257 for high osmolality contrast media), and could offset
the hospital's differential cost for low osmolality contrast media by
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>50% ($671$130) . Because many larger hospitals purchase contrast
media below list price through various contracts, the reduction in
the hospital's differential cost would likely be even greater .
Numerous other factors must be considered when selecting a
contrast medium for use in an angiographic procedure . For example,
although the analysis of Powe et al . considers the costs incurred, it
fails to estimate the opportunity cost or potential loss of revent e by
the hospital or physician, or both, due to the increased average time
treating adverse reactions in patients given high osmolality contrast
media. Other important perspectives omitted from the authors'
analysis include those of the patient, physician and staff . A recent
study by Hopper and Matthews (4) demonstrated that when low risk
patients were given a choice of contrast media as part of an informed
consent procedure, nearly half of them opted for low over high
osmolality contrast media, even if they were required to pay a cost
differential of $100 to $150. In that study, 63% of the low risk
patients surveyed felt the choice of contrast media should be left to
the individual patient . Another recent study, by Debatin et al . (5),
demonstrated that physicians would be inclined to use low osmolal-
ity contrast media universally if given the choice . That study
showed that when physicians were allowed to decide within certain
guidelines which patients were at high risk for an adverse reaction .
over time they expanded the definition of a high risk patient and
increased their use of low osmclality contrast media .
The report by Powe et . al . is an analysis of data previously
published in the New England Journal of Medicine (6) . Although the
authors carefully documented information regarding costs incurred,
the data used for both analyses are compromised by the extensive
screening of potential study participants . Only 26% of the cardiac
catheterization patients examined at Johns Hopkins during the study
period (50511955) were enrolled in the study because of numerous
preselection criteria, among which were refusal of the patient to give
informed consent, unwillingness on the part of the physician to
enroll patients, a clinical determination that low osmolality contrast
media was warranted, the likelihood of another contrast-enhanced
study within 48 h, patient history of contrast reaction of preexisting
renal insufficiency . Even given these enrollment biases . the inci .
dence of mild and moderate adverse events was mr-e than three
times higher with high than with low osmolality contrast media . In
addition, the average: per-patient cost of treating reactions was much
greater than in the high than in the low osmolality contrast media
group. In a trial with randomized, consecutive patient +rollment, it
is likely that the incidence of adverse events and the per-patient
treatment costs of adverse events in the high osmolality contrast
media group would be even higher in comparison with the low
osmolality contrast media group .
In this study (6), as in previous comparative studies, the single
greatest risk factor, and the only one totally controlled by the
physician, was the choice of contrast medium . The study showed
that even in patients at very low risk, adverse events were three
times more frequent among patients given high osmolality contrast
media. The study also showed that the cost of treating adverse
reactions in can be significantly higher in a high than in a low
osmolality contrast media group. Despite significant protocol biases
in favor of high osmolality contrast media, the analysis of Powe et
al . demonstrated that the differential cost to the hospital of using low
osmolality contrast media may be reduced by >50% when the cost
of treating adverse reactions is considered . Considering the actual
price and volume of contrast media used today, universal use of low
osmolality contrast media for angiocardiographic procedures may
be cost-effective from a societal point of view . These findings lend
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additional support to the argument that factors other than the list
price of low osmclality contrast media need to be considered when
deciding which type of contrast media to use for angiocardiographic
procedures .
Ultimately, regardless of any cost differential, the patients'
welfare should be the primary consideration . As the 1993 ACC
guidelines on the use of contrast media (7) indicate, individual
patients in consultation with their physicians are best suited to make
the decision regarding the use of high or low osmolality contrast
media for an angiographic procedure .
ADEOYE Y. OLUKOTUN, MD, FACC
Squibb Diagnostics
P
.O . Box 45,70
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Zbrozek raises two issues concerning ou' • economic analysis of low
versus liigh osmolality contrast media in diagnostic angiocardio
graE hy . The first concerts the most appropriate estimate of the cost
of adverse reactions . Our analysis protocol was designed to com-
pare the cost (from three perspectives) of high versus low osmolality
contrast media-induced adverse reactions of any severity and
contrast material costs. In our baseline analysis, we used the mean
costs that we observed for high and low osmolality contrast media-
induced reactions . After examining the frequency and costs of
adverse reactions by subgroups defined by severity level, it became
evident that the magnitude of the offset of the difference in material
cost related to o, . verse reactions was driven by level 4 (severe)
adverse reactions . We, therefore, examined the sensitivity of our
results to the -ost of level 4 adverse reactions . This post-hoc
analysis showed an estimated 15% offset of the difference in material
cost between high and low osmolality contrast media when pooled
level 4 costs were used . The observed costs within each severity
level were higher among patients receiving high than among patients
receiving low osmolality contrast media . Although, the differences
in the mean cost of adverse reactions of a given severity by type of
contrast media were not statistically significant, our power to detect
a true difference was low . We believe that the approach we took in
our analyses was reasonable . However, our data are presented in
sufficient detail to permit others to make their own assumptions,
calculations and conclusions, as both Zbrozek and Olukotun have
done .
The second issue raised by Zbrozek is that of the impact of
